News Formal

Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales Soar

  • 📰 ForbesTech
  • ⏱ Reading Time:
  • 9 sec. here
  • 11 min. at publisher
  • 📊 Quality Score:
  • News: 38%
  • Publisher: 59%

Eli Lilly ニュース

Novo Nordisk,Tirzepatide,Zepbound

Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.

Pharma titan Eli Lilly on Thursday reported strong demand for its weight loss and diabetes drugs Zepbound and Mounjaro, smashing analysts’ expectations in the face ofEli Lilly reported $11.3 billion in revenue and $2.97 billion in net profit for the second quarter of 2024.

Lilly reported $3.28 earnings per share, besting expectations of $2.74, and raised the range of its annual forecast $2.05 to earnings per share between $15.10 to $15.60.

 

コメントありがとうございます。コメントは審査後に公開されます。
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 318. in JP

日本 最新ニュース, 日本 見出し